Disclosed herein are RNA molecules with particular nucleotide sequences that, through Watson-Crick base pairing, enable the RNAs to form a hydrogel.
1. A synthetic RNA comprising a 5′ region, a first loop region, an inter-loop region, a second loop region and a 3′ region, wherein through Watson-Crick pairing, the synthetic RNA has the secondary structure of A,
wherein said 5′ region consists of the sequence of SEQ ID NO: 14; said first loop region consists of a nucleotide sequence selected from the group consisting of SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, and SEQ ID NO: 20; said inter-loop region consists of the nucleotide sequence selected from SEQ ID NO: 21 and SEQ ID NO: 22; said second loop region consists of the nucleotide sequence of SEQ ID NO: 23; and said 3′ region consists of a nucleotide sequence selected from SEQ ID NO: 24 and 25.
2. The synthetic RNA oligonucleotide of claim 1 , wherein said oligonucleotide consists of a nucleotide sequence selected from the group consisting of SEQ ID NO: 3, 8, 10, 11, 12 and 13.
3. A hydrogel comprising the synthetic oligonucleotide of claim 2 .
4. A synthetic RNA oligonucleotide of claim 1 comprising tandem repeats of a nucleotide sequence selected from the group consisting of SEQ ID NO: 3, 8, 10, 11, 12 and 13.
5. The synthetic oligonucleotide of claim 4 , where said tandem repeats are separated by a linking/intervening nucleotide sequence.
6. The synthetic oligonucleotide of claim 1 , wherein said oligonucleotide forms a hydrogel.
7. A synthetic oligonucleotide that encodes a sequence selected from the group consisting of SEQ ID NO: 3, 8, 10, 11, 12 and 13.
8. A pharmaceutical composition comprising a synthetic oligonucleotide consisting of the nucleotide sequence of SEQ ID NO: 3, 8, 10, 11, 12 and 13.
9. A pharmaceutical composition comprising a hydrogel comprising an oligonucleotide with the nucleotide sequence of SEQ ID NO: 3, 8, 10, 11, 12 and 13.